

Care report

Vandetanib in a child affected by neurofibromatosis type 1 and medullary thyroid carcinoma with both *NF1* and homozygous *RET* proto-oncogen germ-line mutations

Short running title: Vandetanib usage in medullary thyroid cancer with both NF1 and RET mutation

Begumhan Demir Gundogan¹, Fatih Sagcan¹, Sevcan Tug Bozdogan², Yuksel Balci³, Ferah Tuncel Daloglu⁴, Elvan Caglar Citak¹

¹Mersin University Faculty of Medicine, Department of Pediatric Oncology, Mersin, Turkey

²Cukurova University Faculty of Medicine, Department of Medical Genetics, Adana, Turkey

³Mersin University Faculty of Medicine, Department of Radiology, Mersin, Turkey

⁴Mersin University Faculty of Medicine, Department of Pathology, Mersin, Turkey

What is already known on this topic?

Medullary thyroid carcinoma or C-cell hyperplasia are usually associated with other endocrine tumors or a patients with MEN2 clinical findings. germline mutations in both *NF1* and *RET* proto-oncogene have been reported only in a patient with thyroid C-cell hyperplasia. Although Vandetanib is frequently used in thyroid medullary carcinoma in the adult age group, there is little data regarding its use in the childhood age group.

What this study adds?

This is the first report the presence of a double germline mutation involving both *NF1* and *RET* genes and treated with vandetanib

Abstract

Cases of neurofibromatosis type 1 (NF1)-associated medullary thyroid carcinoma (MTC) or C-cell hyperplasia are rarely associated with other endocrine tumors or cases with a multiple endocrine neoplasia type 2 (MEN2). In these patients, mutations were detected in the *NF1* gene but no mutations were detected in the *RET* gene. Although vandetanib has been shown to improve progression-free survival in adults with advanced MTC, data in pediatric patients are limited. Herein, we report the use and outcome of vandetanib in a pediatric MTC case in which *NF1* gene and *RET* proto-oncogen mutation were identified together.

Keywords: Medullary thyroid carcinoma, vandetanib, *RET* proto-oncogene, *NF1* gene, children

Correspondence and Reprint Request Address:

Elvan Caglar Citak, MD

Professor of Pediatric Oncology

Mersin University Faculty of Medicine Department of Pediatric Oncology

Mersin, Turkey

e-mail address: caglarcitak@yahoo.com

0000-0003-1451-1373

Submitted: 24-Mar-2020;

Accept (01-Jul-2020)

Introduction

Neurofibromatosis Type I (NF1) is a common, autosomal dominant multi systemic neurocutaneous disorder. An increased frequency of various endocrine pathologies such as central puberty early development, short stature, diencephalic syndrome, growth hormone deficiency or growth hormone hypersecretion has been reported in children and also pheochromocytoma, parathyroid carcinoma, parathyroid adenoma, somatostatin producing neuroendocrine tumor, duodenal carcinoid tumor producing somatostatin, thyroid papillary carcinoma and pheochromocytoma have been described in patients with NF1 (1-3). Medullary Thyroid Carcinoma (MTC) is a neuroendocrine tumour arising from the calcitonin producing parafollicular C-cells of the thyroid. It accounts for approximately 1-2% of all thyroid cancers. Clinically, 70-80% of MTCs are sporadic, while 20-30% are inherited in autosomal dominant inheritance (4). Hereditary MTCs may be part of multiple endocrine neoplasia (MEN) type 2 and occur in three different clinical forms as MEN2A, MEN2B and familial MTC. Mutated "REarrangement during Transfection" (*RET*) proto-oncogene plays a very significant role in the development of human neuroendocrine tumors and tumor syndromes. *RET* proto-oncogene mutation has been reported in both sporadic and familial cases (4).

Cases of NF1-associated MTC or C-cell hyperplasia are rarely associated with other endocrine tumors or with MEN2 clinical findings. In these patients, mutations were detected in the *NF1* gene but no mutations were detected in the *RET* gene. (5-12). To our knowledge, germline mutations in both *NF1* and *RET* proto-oncogene have been reported only in one patient with thyroid C-cell hyperplasia, but no simultaneous mutation of these two genes in MTC has been reported (12).

In this article, we present a 15-year-old male patient diagnosed with both NF1 and MTC, and also had mutations in both NF1 and RET genes, and want to discuss the effectiveness of vandetanib therapy in MTC.

Case report

A 15-year-old boy admitted to a hospital with progressively increasing midline swelling for 2 months. Physical examination revealed firm and mobile 3×2 cm swelling on the left side of the neck, multiple lymph nodes, multiple café-au-lait macules, inguinal and axillary freckling. Lisch nodule was detected in the eye examination. Cranial magnetic resonance imaging (MRI) showed the focal areas of the signal intensity and bilateral optic glioma. Family history revealed that his brother and mother had similar findings and also his mother had neurofibromas. Cervical ultrasonography (US) and computed tomography (CT) showed a heterogeneous mass lesion in the left thyroid lobe and multiple lymphadenopathy. Total blood count and biochemical analysis were within normal range. Thyroid-stimulating hormone (TSH), free T3 and free T4 levels were 21.038 μ IU/ml (0.72-11 μ IU/ml), 6.28 pmol/L (8-22 pmol/L) and 14.76 pmol/L (8-22 μ IU/ml), respectively. After the cervical nodes were resected and pathological investigation demonstrated metastasis of MTC, the patient was referred to the department of pediatric surgery. Preoperative calcitonin and carcinoembryonic antigen (CEA) levels were 2000 pg/mL (0-8.4 pg/mL) and 116,52 ng/ml (0-2.5 ng/ml), respectively. The patient was admitted to our department after total thyroidectomy and radical neck dissection. He was investigated for MEN syndrome. Serum parathyroid hormone, serum gastrin, 24 hour urinary catecholamine and metanephrine levels were within normal range.

Histopathologic examination showed MTC with presence of perineural and lymphovascular invasion (Figure 1-A,B,C,D,E,F). Due to the residual thyroid tissue and bilateral pathological lymph nodes detected on Tc99m-pertechnetate thyroid scintigraphy and positron emission tomography, the patient was re-operated but they could not be completely removed. The patient's stage was T2N1aM0 (Stage III) according to the Tumor Node Metastasis system proposed by the "American Joint Committee on Cancer" (13). Molecular testing revealed a heterozygous mutation in *NF1* gene [IVS38-2A>G(c.5610-2A>G)] both in our patient and his brother. There was no *NF1* related mutation in his mother. Also homozygous *RET* proto-oncogene mutation [c.2671T>G (p.5891A) (p.Ser891Ala)] was found in the patient, heterozygous mutation in his mother, father and brother (Figure 2). As a result of incomplete removal of lymph nodes and remaining thyroid tissue, serum calcitonin level was 1563 pg/ml and serum CEA level was 57.28 ng/ml and vandetanib treatment was initiated at a dose of 300 mg/day. Serum calcitonin levels at 6th, 12th and 24th months of treatment were 34.7 pg / ml, 4.4 pg / ml and 1.2 pg / ml, and CEA levels were 12 ng / ml, 3.2 ng / ml and 1.1 ng / ml, respectively. The patient has been on vandetanib treatment for 32 months and no residual tissue and lymphadenopathy were detected on the neck tomography taken at the 30th month of the treatment. No side effects were observed during vandetanib treatment in our patient in this period.

Discussion

Besides leukemia, somatic *NF1* mutations have been reported in various cancers occurring in many different regions such as breast, colorectum, urothelium, lung, ovary, skin and nerve tissues (14). In addition, pheochromocytoma, parathyroid carcinoma, somatostatin producing neuroendocrine tumors, duodenal carcinoid tumors, and thyroid papillary carcinoma are reported endocrine neoplasms in patients with *NF1*. In these patients, it can be assumed that *NF1* mutations predispose to the development of endocrine tumors by affecting the growth and differentiation of parafollicular C cells, parathyroid cells and other cells from which different endocrine tumors develop.

To our knowledge, in the literature, MTC has not been reported in patients with *NF1* mutation. In these patients, the cause of this association is unclear because no germ-line mutation in the *RET* gene could be demonstrated. Mutations in both the *NF1* and *RET* genes have been described to date only in one case with thyroid C cell hyperplasia (12). Our case is remarkable since it is the first case of MTC in which both *NF1* gene and *RET* proto-oncogene mutation are identified simultaneously. MTC is a rare tumor originating from the parafollicular or C-cells of the thyroid gland. MTC is sporadic in 75% of patients and usually occurs in the fourth to sixth decade of life. Less commonly, hereditary MTCs are found in MEN2A or MEN2B or as a part of familial MTC (15). *RET* proto-oncogene mutation is detected in almost all hereditary cases and in more than 40% of sporadic cases (15).

In our patient, homozygous mutation was detected in codon891 in *RET* gene. The S891A mutation is first described by Hofstra et al (16) at 1997 and associated with MEN 2A and MTC. Less than 5% of all MTC patients reported to date have *RET* mutation p.S8191 and this mutation is reported to be heterozygous because *RET* oncogene, acts dominantly as like all oncogenes (17). Giacché et al (18) as a result of the analysis made to 251 relatives of individuals with 28 Ser891Ala mutations, they stated that 108 people had asymptomatic carriage and 64 of them had thyroidectomy. As a result of histological examination, they reported that the mean age of patients with C-cell hyperplasia, micro-MTC and MTC was 30.2 \pm 13.7, 37.9 \pm 10.3 and 55.0 \pm 14.7, respectively, and that malignancy development increased with age in individuals carrying the pSer891A mutation. As a result of the ItaMEN study where the germline *RET* mutations of 250 families with hereditary MTC were evaluated, the p.Ser891Ala mutation was 9.2% and was lower than other European studies (19). Also Schulte KM et al (20) stated that they found p.Ser891Ala mutation as 5% in patients followed up for MEN 2A. According to our knowledge there is only one study about the frequency of S891A mutation in Turkish patients (21). In this study 12 different *RET* oncogene mutations were detected in 32 of 155 patients who were diagnosed with MTC as part of MEN2 or isolated, and S891A mutation was reported in 2 patients (6%). In this case the mutation has been detected as homozygous and to our knowledge it was not reported previously. The S891A mutation poses a moderate risk for MCT development according to the American Thyroid Association (ATA). The recommended approach according to ATA in individuals with moderate-risk *RET* mutations is to follow annual calcitonin and perform a total thyroidectomy when high values are detected (22). The mothers, fathers and siblings of our patients with heterozygous S891A mutations did not have any symptoms, pathological examination or laboratory findings in favor of cancer. Since the mother and father carry a moderately risky mutation according to ATA criteria and MTC risk will increase in later years, prophylactic thyroidectomy was recommended but they did not accept. Similarly, the family preferred long-term follow-up instead of total thyroidectomy for the other child with a heterozygous S891A mutation.

The *NF1* gene encodes neurofibromin, a GTPase-activating protein that negatively regulates the Ras/mitogen-activated protein kinase (MAPK) signalling pathway (23). Loss-of-function mutations in *NF1* lead to uncontrollable activation of kinase and tumorigenesis. Also, the *RET* protooncogene encodes a receptor tyrosine kinase (RTK) that mediates extracellular neurotropic signaling to intracellular transduction pathways including the MAPK/ERK pathway (24). We think that these two

diseases coincidentally, because the MTC developed in our patient did not work on a common path according to our information about both the *NF1* gene and the *RET* oncogene.

Our patient was investigated for MEN2 due to *RET* protooncogen mutation and MTC. In the family history, we learned that there were no patients with thyroid disease and therefore operated. *RET* proto-oncogen mutation analysis of the parents revealed that they were carriers of germ-line S891A mutation. On three-generation pedigree analysis no family member with cancer including MTC was seen. Although we could not perform the molecular tests of the *RET* gene for the rest of the family since they lived in different cities, we thought the maternal grandmother and paternal grandfather as carrier because they were siblings and the case had a homozygous mutation. The case was thought to be familial MTC although there was no clinical or laboratory finding in any of the heterozygotes despite the mutation in the family; and currently follow-up was performed without prophylactic thyroidectomy.

In the follow-up of our patient, we thought that vandetanib treatment would be appropriate since residual tissue was still present after the second operation. Vandetanib is an orally available tyrosine kinase inhibitor that targets vascular endothelial growth factor dependent tumor angiogenesis and epidermal growth factor receptor, *RET* and *RET* dependent tumor cell proliferation (25). Several studies have evaluated the efficacy of vandetanib in the treatment of advanced MTC. In the ZETA trial, 331 patients with 5% local advanced stage and 95% metastatic MTC were randomized to vandetanib and placebo. At the end of the study, it was determined that the median survival of 19.3 months in the placebo group and the median 30.5 months in the vandetanib group were progression-free survival and a significant difference was found between the two groups (26). In a meta-analysis, 300 mg of vandetanib treatment was demonstrated to have a better objective response than 150 mg of vandetanib treatment (27). When compared to 150 mg and 300 mg vandetanib treatments, Hu MI et al (28) showed that administration of 300 mg increased overall response rate.

The efficacy of vandetanib in childhood and adolescence was investigated in 16 patients aged 5-18 years with locally advanced or metastatic MEN2B-associated MTC. In this study, the dose of vandetanib was as 100 mg/m². M918T *RET* germline mutation was present in 15 patients and 7 of them (47%) had a partial response (29). Kraft et al (30) reported that the best partial response was observed in median 6.1 years in children treated with vandetanib, which lasted a median of 7.4 years and that progression-free survival was 6.7 years. Our patient has been receiving vandetanib for 2 years and serum calcitonin and CEA levels gradually decreased and reached the normal reference range. Since the dose we administer is higher than the dose in other pediatric studies and our patient is 15 years old, we think that the 300 mg/day dose stated in adult studies may have contributed to our good response. Also, considering that vandetanib suppresses *RET* oncogene and *RET* oncogene dependent cell proliferation, it may be thought that the high dose we applied may be more effective due to the homozygous mutation in our patient.

In conclusion, it should be kept in mind that different endocrinological tumors may develop with *NF1* rarely and the patients should be carefully evaluated in this regard. Furthermore, we think that vandetanib dose for children with MTC may be the same as in adults but this needs to be supported by further studies of larger sample size.

Declaration: The authors declare that there are no conflicts of interest regarding the publication of this paper. Written informed consent was obtained from the patient's parents for publication of this case report and the accompanying images.

References

1. Bizzarri C, Bottaro G. Endocrine implications of neurofibromatosis 1 in childhood. *Horm Res Paediatr* 2015;83:232-241.
2. Wong CL, Fok CK, Tam VH. Concurrent primary hyperparathyroidism and pheochromocytoma in a Chinese lady with neurofibromatosis type 1. *Endocrinol Diabetes Metab Case Rep*. 2018;28;2018.
3. Kim BK, Choi YS, Gwoo S, Park YH, yang SI, Kim JH. Neurofibromatosis type 1 associated with papillary thyroid carcinoma incidentally detected by thyroid ultrasonography: a case report. *J Med Case Rep* 2012;6:179
4. Taccaliti A, Silvetti F, Palmonella G, Boscaro M. Genetic alterations in medullary thyroid cancer: diagnostic and prognostic markers. *Curr Genomics* 2011;12:618-625.
5. Hansen OP, Hansen M, Hansen HH, Rose B. Multiple endocrine adenomatosis of mixed type. *Acta Med Scand* 1976;200:327-331.
6. Yoshida A, Hatanaka S, Ohi Y, Umekita Y, Yoshida H. Von Recklinghausen's disease associated with somatostatin-rich duodenal arcinoid (somatostatinoma), medullary thyroid carcinoma and diffuse adrenal medullary hyperplasia. *Acta Pathol Jpn* 1991;41:847-856.
7. Barbot N, Calmettes C, Schuffenecker I, Saint-André JP, Franc B, Rohmer V, Jallet P, Bigorgne JC. Pentagastrin stimulation test and early diagnosis of medullary thyroid carcinoma using an immunoradiometric assay of calcitonin. Comparison with genetic screening in hereditary medullary thyroid carcinoma. *J Clin Endocrinol Metab* 1994;78:114-120.
8. Pages A, Marthy C, Baldet P, Péraldi R. Neurofibromatosis—thyroid medullary carcinoma—pheochromocytoma syndrome. *Arch Anat Pathol* 1970;18:137-142.
9. Schimke RN. Multiple endocrine neoplasia: how many syndromes? *Am J Med Genet* 1990;37:375-383.
10. Segni Massa R, Bonifacio V, Bonifacio V, Tartaglia F, Pucarelli I, Marzullo A, Pasquino AM. Thyroid C-cell hyperplasia in an adolescent with neurofibromatosis type 1. *Horm Res* 2001;56:63-66.
11. Gieldon L, Masjkur JR, Richter S, Därr R, Lahera M, Aust D, Zeugner S, Rump A, Hackmann K, Tzschach A, Januszewicz A, Prejbisz A, Eisenhofer G, Schrock E, Robledo M, Klink B. Next-generation panel sequencing identifies *NF1* germline mutations in three patients with pheochromocytoma but no clinical diagnosis of neurofibromatosis type 1. *Eur J Endocrinol* 2018;178:K1-K9.
12. Ercolino T, Lai R, Giachè V, Melchionda S, Carella M, Delitala A, Mannelli M, Fanciulli G. Patient affected by neurofibromatosis type 1 and thyroid C-cell hyperplasia harboring pathogenic germ-line mutations in both *NF1* and *RET* genes. *Gene* 2014;536:332-335
13. Edge SB, Byrd DR, Compton CC, Gershengwald JE, Brookland RK, Meyer L, Gress DM, et al. *AJCC cancer staging manual* (7th ed) New York, NY: Springer. 2010

14. Mahalingam M. NF1 and Neurofibromin: Emerging Players in the Genetic Landscape of Desmoplastic Melanoma. *Adv Anat Pathol* 2017;24:1-14
15. Fagin JA, Wells Jr. SA. Biologic and clinical perspectives on thyroid cancer. *N Engl J Med* 2016;15:1054-1067.
16. Hofstra RM, Fattoruso O, Quadro L, Wu Y, Libroia A, Verga U, Colantuoni V, Buys CH. A novel point mutation in the intracellular domain of the ret protooncogene in a family with medullary thyroid carcinoma. *J Clin Endocrinol Metab* 1997;82:4176-4178.
17. Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH, Di Fiore PP. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. *Science* 1995;267: 381-383
18. Giacché M, Panarotto A, Tacchetti MC, Tosini R, Campana F, Mori L, Cappelli C, Pirola I, Lombardi D, Pezzola DC, Casella C, Castellano M. p.Ser891Ala RET gene mutations in medullary thyroid cancer: Phenotypical and genealogical characterization of 28 apparently unrelated kindreds and founder effect uncovering in Northern Italy. *Hum Mutat* 2019;40:926-937
19. Romei C, Mariotti S, Fugazzola L, Taccaliti A, Pacini F, Opocher G, Mian C, Castellano M, degli Uberti E, Ceccherini I, Cremonini N, Seregini E, Orlandi F, Ferolla P, Puxeddu E, Giorgino F, Colao A, Loli P, Bondi F, Cosci B, Bottici V, Cappai A, Pinna G, Persani L, Verga U, Boscaro M, Castagna MG, Cappelli C, Zatelli MC, Faggiano A, Francia G, Brandi ML, Falchetti A, Pinchera A, Elisei R; ItaMEN network. Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. *Eur J Endocrinol* 2010;163:301-308
20. Schulte KM, Machens A, Fugazzola L, McGregor A, Diaz-Cano S, Izatt L, Aylwin S, Talat N, Beck-Peccoz P, Dralle H. The clinical spectrum of multiple endocrine neoplasia type 2a caused by the rare intracellular RET mutation S891A. *J Clin Endocrinol Metab* 2010;95:E92-97
21. Tekin IM, Onay H, Aykut A, Karaca E, Atik T, Turan C, Özger G, Erdogan M, Ozkinay F. RET mutation spectrum in Turkish cases with medullary thyroid carcinoma: definition of a novel K710R mutation. *J Clin Res Pediatr Endocrinol* 2015;7(Suppl 2):90
22. Türkiye Endokrin ve Metabolizma Derneği Tiroid Hastalıkları Tanı ve Tedavi Klavuzu 2019, http://temd.org.tr/admin/uploads/tbl_kilavuz/20190426165340-2019tbl_kilavuze72e4ddf38.pdf
23. Laycock-van Spyk SL, Thomas N, Cooper DN, Upadhyaya M. Neurofibromatosis type 1-associated tumours: Their somatic mutational spectrum and pathogenesis. *Hum Genomics* 2011;5:623-690
24. Cortés JMR, Zerón HM. Genetics of Thyroid Disorders. *Folia Med (Plovdiv)* 2019;61:172-179
25. Herbst RS, Heymach JV, O'Reilly MS, Onn A, Ryan AJ. Vandetanib (ZD6474), an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. *Expert Opin Investig Drugs* 2007;16:239-249.
26. Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. *J Clin Oncol* 2012;30:134-141.
27. Tsoli M, Alexandraki KI, Spei ME, Kaltsas GA, Daskalakis K. Anti-tumor activity and safety of multikinase inhibitors in advanced and/or metastatic thyroid cancer: A systematic review and network meta-analysis of randomized controlled trials. *Horm Metab Res.* 2020;52:25-31
28. Hu MI, Elisei R, Dedecjus M, Popovtzer A, Druce M, Kapiteijn E, Pacini F, Locati L, Krajewska J, Weiss R, Gagel RF. Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer. *Endocr Relat Cancer.* 2019;26:241-250
29. Fox E, Widemann BC, Chuk MK, Marcus L, Aikin A, Whitcomb PO, Merino MJ, Lodish M, Dombi E, Steinberg SM, Welss SA, Balis FM. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma. *Clin Cancer Res* 2013;19:4239-4248.
30. Kraft IL, Akshintala S, Zhu Y, Lei H, Derse-Anthony C, Dombi E, Steinberg SM, Lodish M, Waguespack SG, Kapustina O, Fox E, Balis FM, Merino MJ, Meltzer PS, Glod JW, Sherm JF, Widemann BC. Outcomes of children and adolescents with advanced hereditary medullary thyroid carcinoma treated with vandetanib. *Clin Cancer Res* 2017;24:753-765.

Figure 1.





Figure 2.



Uncorrected proof